BCRX
Price
$7.45
Change
+$0.39 (+5.52%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
1.46B
33 days until earnings call
RARE
Price
$40.00
Change
-$0.85 (-2.08%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
3.77B
27 days until earnings call
Ad is loading...

BCRX vs RARE

Header iconBCRX vs RARE Comparison
Open Charts BCRX vs RAREBanner chart's image
BioCryst Pharmaceuticals
Price$7.45
Change+$0.39 (+5.52%)
Volume$51.05K
Capitalization1.46B
Ultragenyx Pharmaceutical
Price$40.00
Change-$0.85 (-2.08%)
Volume$22.38K
Capitalization3.77B
BCRX vs RARE Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. RARE commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and RARE is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (BCRX: $7.06 vs. RARE: $40.85)
Brand notoriety: BCRX: Notable vs. RARE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 128% vs. RARE: 88%
Market capitalization -- BCRX: $1.46B vs. RARE: $3.77B
BCRX [@Biotechnology] is valued at $1.46B. RARE’s [@Biotechnology] market capitalization is $3.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $370.67B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 4 bearish.
  • RARE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both BCRX and RARE are a good buy in the short-term.

Price Growth

BCRX (@Biotechnology) experienced а -12.30% price change this week, while RARE (@Biotechnology) price change was -6.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.05%. For the same industry, the average monthly price growth was +3.04%, and the average quarterly price growth was -1.59%.

Reported Earning Dates

BCRX is expected to report earnings on May 07, 2025.

RARE is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.77B) has a higher market cap than BCRX($1.46B). RARE YTD gains are higher at: -2.900 vs. BCRX (-6.117). BCRX has higher annual earnings (EBITDA): -24.12M vs. RARE (-461.54M). RARE has more cash in the bank: 622M vs. BCRX (330M). RARE has less debt than BCRX: RARE (34.1M) vs BCRX (809M). RARE has higher revenues than BCRX: RARE (523M) vs BCRX (413M).
BCRXRAREBCRX / RARE
Capitalization1.46B3.77B39%
EBITDA-24.12M-461.54M5%
Gain YTD-6.117-2.900211%
P/E RatioN/AN/A-
Revenue413M523M79%
Total Cash330M622M53%
Total Debt809M34.1M2,372%
FUNDAMENTALS RATINGS
BCRX vs RARE: Fundamental Ratings
BCRX
RARE
OUTLOOK RATING
1..100
6913
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
69
Overvalued
PROFIT vs RISK RATING
1..100
71100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5381
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (3) in the Biotechnology industry is significantly better than the same rating for RARE (69). This means that BCRX’s stock grew significantly faster than RARE’s over the last 12 months.

BCRX's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as RARE (100). This means that BCRX’s stock grew similarly to RARE’s over the last 12 months.

BCRX's SMR Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that BCRX’s stock grew similarly to RARE’s over the last 12 months.

BCRX's Price Growth Rating (53) in the Biotechnology industry is in the same range as RARE (81). This means that BCRX’s stock grew similarly to RARE’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that BCRX’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXRARE
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
74%
Momentum
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
73%
MACD
ODDS (%)
Bearish Trend 4 days ago
72%
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 8 days ago
79%
Bearish Trend 8 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
79%
Aroon
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
84%
View a ticker or compare two or three
Ad is loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with BEAM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
-2.35%
BEAM - BCRX
39%
Loosely correlated
+0.04%
PRTA - BCRX
39%
Loosely correlated
-0.68%
DNLI - BCRX
38%
Loosely correlated
+0.79%
RIGL - BCRX
37%
Loosely correlated
-3.66%
RARE - BCRX
37%
Loosely correlated
-0.32%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with DNLI. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-0.32%
DNLI - RARE
43%
Loosely correlated
+0.79%
CRNX - RARE
41%
Loosely correlated
-0.68%
INZY - RARE
40%
Loosely correlated
-1.45%
ARWR - RARE
39%
Loosely correlated
+0.48%
PRTA - RARE
38%
Loosely correlated
-0.68%
More